Last updated: February 22, 2026
What Is NDC 61755-0020?
NDC 61755-0020 refers to a specific pharmaceutical product listed under the National Drug Code (NDC). Based on publicly available data, this code corresponds to Humira (adalimumab) 40 mg/mL, pre-filled pen. Humira is an immunosuppressive biologic used to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and other inflammatory conditions.
Market Overview
Market Size and Growth
Humira's global sales peaked at $21.2 billion in 2021, according to company filings and IQVIA reports. The biologic's market penetration remains strong, driven by its indications, safety profile, and once-monthly dosing regimen.
Competition
The key competitors in the biologic TNF-alpha inhibitors segment include:
- Enbrel (etanercept)
- Remicade (infliximab)
- Cimzia (certolizumab pegol)
- Skyrizi (risankizumab) and others targeting similar immune pathways.
Biosimilars of Humira launched in various markets starting 2023, notably in Europe and the US, where multiple competition pathways impact price and volume.
Regulatory Environment
Humira’s patent protection in the US expired in January 2023, opening the market for biosimilar competition. Several biosimilars have since launched, resulting in significant price erosion.
Price Dynamics and Projections
Historical Pricing
- Originator price in the US (pre-patent expiry): Approximately $5,600 per 40 mg pre-filled pen (per dose).
- Post-patent expiry: Biosimilar versions entered the market at prices approximately 30-50% below the originator price, around $2,800–$3,200 per dose initially.
Factors Influencing Future Price Trends
- Market penetration of biosimilars: As biosimilars gain acceptance and switch patients from originators, prices are expected to stabilize at lower levels.
- Reimbursement policies: Managed care and payer strategies will influence actual transaction prices.
- Global market dynamics: In European markets, biosimilar adoption has been robust, pushing prices down by 40-60%.
Price Projection Assumptions
- Short-term (1-2 years): Continued price erosion as biosimilar uptake accelerates, with retail prices potentially dropping by an additional 10-20% as market shares stabilize.
- Medium-term (3-5 years): Price plateau at approximately $2,000–$2,500 per dose in the US, with regional variation based on healthcare policies and biosimilar acceptance.
- Long-term: Further competitive pressures and patent exclusivity periods may lead to sustained price reductions, especially in emerging markets.
Revenue Impact
Revenue from NDC 61755-0020 in the US is likely to decline by 50-60% over the next 3 years due to biosimilar competition, although overall global sales may stabilize with increased use in countries with less biosimilar penetration.
Market Entry and Distribution Strategy
For companies or investors considering entry, the following points are critical:
- Market timing: Biosimilar launch timing significantly influences price erosion.
- Pricing strategy: Competitive pricing below originator levels can accelerate adoption.
- Partnerships: Collaborations with payers can foster quicker market penetration.
Summary
Humira (NDC 61755-0020) remains a high-revenue biologic. Patent expiration catalyzed biosimilar competition, leading to aggressive price declines across multiple markets. Future pricing will depend on biosimilar market penetration, regional policies, and payer strategies. In the US, prices are expected to stabilize at about half of pre-expiry levels over the next 2-3 years, with continued erosion possible in the longer term.
Key Takeaways
- NDC 61755-0020 is associated with Humira, a top-selling biologic.
- Post-patent expiry, biosimilar entry triggered significant price declines.
- US prices are projected to decrease by 50-60% in 3 years.
- Market share shifts and payer policies will influence long-term pricing.
- Global markets show diverse adoption rates, affecting overall revenue.
FAQs
Q1: How soon will biosimilar competition impact prices in the US?
A: Significant price reductions are already underway since January 2023, with further erosion expected over the next 1-2 years.
Q2: Will the original Humira manufacturer maintain premium pricing?
A: Likely not, as biosimilar competition offers similar efficacy at lower prices, pushing originator prices downward.
Q3: Are other biosimilars approved in the US?
A: Yes. Multiple biosimilar versions have been approved and launched, including Amgen's Amjevita and Samsung Bioepis's Hadlima.
Q4: How does biosimilar uptake differ between regions?
A: Europe has seen rapid adoption with price declines of up to 60%. The US adoption pace is slightly slower due to market and regulatory factors.
Q5: What future market opportunities exist for biosimilar manufacturers?
A: Expansion into emerging markets and biosimilar development for additional indications represent growth avenues.
References
- IQVIA. (2022). Retail and Specialty Pharmacy Data.
- U.S. Food and Drug Administration. (2023). Biosimilar approvals and market entry updates.
- FDA. (2019). Humira patent and biosimilar information.
- Evaluate Pharma. (2022). Biologics market analysis and forecasts.
- Beall, K. (2021). Impact of Biosimilar Competition on Biologic Pricing. Journal of Pharmaceutical Policy and Practice, 14(1), 25–31.
